Article

The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs.

Department of Social Pharmacy, Groningen University Institute for Drug Exploration (GUIDE), Groningen, the Netherlands.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 04/2004; 57(3):328-36.
Source: PubMed

ABSTRACT To evaluate the effect of a letter intervention that was send to both the participants of a population screening and their general practitioners. We also tested what predicting variables influenced the GP to actually prescribe blood pressure lowering drugs (BPLD) or lipid lowering drugs (LLD).
The study design was cross sectional, in the PREVEND outpatient clinic in Groningen University Hospital, the Netherlands. We used the clinical data of the 8592 subjects that participated in the first screening of the PREVEND study. Data on drug use was collected from community pharmacies. Drug use was measured the year before and after the screening with the subsequent intervention letter. As control population without intervention, we used the data from the InterAction DataBase (IADB) standardized for the population characteristics of the intervention group. The letter intervention was sent to participants who had shown after screening to have either an elevated blood pressure or plasma cholesterol, and the letter contained the advice to use a BPLD or LLD. Main outcome measures were proportion of patients prescribed BPLD and/or LLD in the year before and after the intervention, and variables that influence the GP to prescribe BPLD and LLD.
Data from the community pharmacy were available from 7567 (88%) subjects. 397 participants (5.2%) received a letter with advice to start a BPLD, and 326 participants (4.3%) received a letter with advice to start a LLD. The prevalence of patients who were using BPLD and LLD before the intervention was not significantly different between the intervention and control group, 16.6 (CI 95% 15.8 -17.5) vs 16.0 and 4.8 (4.4-5.3) vs 4.6, respectively. After the letter intervention, the prevalence of BPLD use was higher in the intervention group compared with the control group (19.4 [18, 5-20, 3]vs 17.0%), as was the prevalence of LLD use (7.1[6.5-7.7) vs 5.4%). The same held true for the incidence of BPLD (3.4[3.0-3.8]vs 2.5%) and LLD use (2.1 [1, 6-2, 4]vs 1.0%), respectively, in the year after the intervention. Univariate and multivariate analysis showed that a higher blood pressure and cholesterol level, but not the presence of other cardiovascular risk factors, were associated to with a greater percentage use of a BPLD and a LLD.
A population survey followed by a letter of intervention to both the patient and GP are effective to improve the use of blood pressure and lipid lowering drugs as a primary prevention in patients with hypertension and hyperlipidemia. Our therapeutic advice however, was followed only in about one of the three subjects with hypertension and one of the four subjects with hyperlipidemia. The levels of blood pressure and plasma total cholesterol are important variables influencing the GP to prescribe a BPLD and/or LLD.

0 Followers
 · 
136 Views
  • Source
    Journal of Clinical Hypertension 05/2004; 6(4):164-7. DOI:10.1111/j.1524-6175.2004.02874.x · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: En la farmacia comunitaria es necesario desarrollar estrategias para valorar y mejorar el conocimiento de los pacientes sobre la enfermedad cardiovascular (ECV). Se investigó la relación entre conocimiento y riesgo cardiovascular (RCV). En 6 farmacias comunitarias de Granada, Sevilla y Málaga (Andalucía ¿ España). Se realizó un estudio observacional descriptivo durante 15 días sobre el conocimiento y RCV de pacientes. Se aplicó un cuestionario con 10 preguntas para valorar el conocimiento sobre factores de RCV y se calculó el RCV. Los análisis estadísticos utilizados fueron T de Student o X cuadrado. En los 257 pacientes incluidos, la edad promedio fue de 60,9 + 10,8 años, el 5,8% de género masculino,13,2% fuman, 79,0% tienen historia de hipertensión, 42,4% de dislipemia, 19,5% de diabetes tipo 2 y 22,6% de ECV. El puntaje promedio de conocimiento fue de 5,8 + 1,8 (IC95%:5,6-6,1) y fue valorado como adecuado en el 60,7%; (IC95%:54,7-66,7%) de los pacientes. El RCV fue: bajo 35,8%, intermedio 21,0% y alto 43,2. Una menor edad, alto nivel educativo y la práctica de actividad física regular, al igual que la percepción de los pacientes de control o normalidad de los factores de RCV se encontraron asociados con puntajes altos o mejor conocimiento. Sin embargo, no se encontraron diferencias signi- significativas en el conocimiento (p>0,05) entre los pacientes con RCV diferente. El conocimiento adecuado de los pacientes sobre los factores de RCV se asocia con una menor edad, alto nivel educativo, práctica de actividad física y percepción de normalidad de los factores de RCV, pero no con el RCV absoluto.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigated whether recommendations given to the treating vascular specialist and the GP by a multidisciplinary team of vascular specialists concerning the medical treatment of risk factors, based on international guidelines, led to an increased medication use in a high-risk population. Data were obtained from 618 patients enrolled in the SMART study, an ongoing single-center prospective cohort study of patients referred to the University Medical Center Utrecht for atherosclerotic vascular diseases. All patients underwent a vascular screening and their physicians received recommendations concerning the medical treatment of newly detected or not yet sufficiently treated vascular risk factors. After a median follow-up of 29 months, questionnaires about medication use were sent to 618 patients; 534 (86%) questionnaires were returned. Actual use of medication was compared with medical treatment recommendation given at baseline. The proportion of patients on antihypertensive medication with hypertension (> or =140/90 mmHg) and not diagnosed with coronary heart disease increased from 56% to 68% (95% confidence interval (95% CI) 2 - 23). The frequency of lipid-lowering medication use increased substantially from 47% to 69% (95% CI 17 - 28). The frequency of glucose-lowering medication use increased slightly from 11% to 14% (95% CI 1 - 7). The use of folic acid increased from 2% to 14% (95% CI 9 - 15) in patients with hyperhomocysteinaemia. Medical treatment recommendations, formulated by a multidisciplinary team, led to a significant increase in medication use. The increase is marginal compared with trends in medication use without this intervention in usual care.
    Cardiovascular Drugs and Therapy 12/2005; 19(6):429-35. DOI:10.1007/s10557-005-6127-8 · 2.95 Impact Factor
Show more

Preview

Download
0 Downloads
Available from